- Home
- MT vs MRNA Comparison
MT vs MRNA Comparison
Compare MT & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MT
- MRNA
- Stock Information
- Founded
- MT 1976
- MRNA 2010
- Country
- MT Luxembourg
- MRNA United States
- Employees
- MT N/A
- MRNA N/A
- Industry
- MT Steel/Iron Ore
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MT Industrials
- MRNA Health Care
- Exchange
- MT Nasdaq
- MRNA Nasdaq
- Market Cap
- MT 20.1B
- MRNA 16.5B
- IPO Year
- MT 1997
- MRNA 2018
- Fundamental
- Price
- MT $23.25
- MRNA $40.27
- Analyst Decision
- MT Buy
- MRNA Hold
- Analyst Count
- MT 4
- MRNA 19
- Target Price
- MT $30.30
- MRNA $79.50
- AVG Volume (30 Days)
- MT 1.4M
- MRNA 7.9M
- Earning Date
- MT 02-06-2025
- MRNA 02-20-2025
- Dividend Yield
- MT 2.15%
- MRNA N/A
- EPS Growth
- MT N/A
- MRNA N/A
- EPS
- MT N/A
- MRNA N/A
- Revenue
- MT $62,279,000,000.00
- MRNA $5,081,000,000.00
- Revenue This Year
- MT N/A
- MRNA N/A
- Revenue Next Year
- MT $2.50
- MRNA N/A
- P/E Ratio
- MT N/A
- MRNA N/A
- Revenue Growth
- MT N/A
- MRNA N/A
- 52 Week Low
- MT $20.52
- MRNA $35.80
- 52 Week High
- MT $28.97
- MRNA $170.47
- Technical
- Relative Strength Index (RSI)
- MT 36.57
- MRNA 42.28
- Support Level
- MT $22.80
- MRNA $38.52
- Resistance Level
- MT $26.35
- MRNA $40.83
- Average True Range (ATR)
- MT 0.41
- MRNA 2.59
- MACD
- MT -0.25
- MRNA 0.12
- Stochastic Oscillator
- MT 12.68
- MRNA 28.38
About MT Arcelor Mittal NY Registry Shares NEW
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA; Brazil; Europe; ACIS; Mining and others. It generates maximum revenue from the Europe segment. Europe segment produces hot-rolled coil, cold-rolled coil, coated products, tinplate, plate, and slab. These products are sold primarily to customers in the automotive, general, and packaging sectors as well as also produce long products consisting of sections, wire rods, rebar, billets, blooms and wire drawing, and tubular products. Geographically, it derives a majority of its revenue from United States.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.